I think it will rise at some point. Still a solid business with organic revenue growth. They increased marketing, sales and development spend which sets them up for the future.
They've also now got a much better SaaS billing model rather than pre-paid credits. Don't underestimate how much better this is. I've done a similar transition and it means billing can be better automated, freeing up dev/admin time. Customers will also love it. Easier to monitor and approve a regular spend which is seen as another expense like other IT SaaS, rather than monitoring credits usage and talking to AMs about how much credit to buy. Makes it easier for CIOs/CFOs to approve, just BAU spend. Easier to sell too. Win win.
Will think about buying more at these levels, I believe it's good value.
- Forums
- ASX - By Stock
- XF1
- Ann: Xref Limited - Interim Report - Half-year ended 31 Dec 2022
Ann: Xref Limited - Interim Report - Half-year ended 31 Dec 2022, page-6
Featured News
Add XF1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.0¢ |
Change
-0.003(1.18%) |
Mkt cap ! $39.70M |
Open | High | Low | Value | Volume |
21.0¢ | 21.3¢ | 21.0¢ | $1.012M | 4.817M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
12 | 15203837 | 21.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
21.5¢ | 372121 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 15173837 | 0.210 |
7 | 2114944 | 0.205 |
1 | 50000 | 0.200 |
1 | 268000 | 0.190 |
1 | 1 | 0.185 |
Price($) | Vol. | No. |
---|---|---|
0.215 | 372121 | 9 |
0.220 | 19562 | 4 |
0.000 | 0 | 0 |
0.000 | 0 | 0 |
0.000 | 0 | 0 |
Last trade - 15.52pm 15/11/2024 (20 minute delay) ? |
Featured News
XF1 (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online